keyword
MENU ▼
Read by QxMD icon Read
search

neutropenic regimen

keyword
https://www.readbyqxmd.com/read/29736867/development-of-a-simplified-multivariable-model-to-predict-neutropenic-complications-in-cancer-patients-undergoing-chemotherapy
#1
Abolfazl Razzaghdoust, Bahram Mofid, Maryam Moghadam
PURPOSE: Neutropenic complications remain the major dose-limiting toxicities of cancer chemotherapy. The aim of this study was to develop and internally validate a comprehensive and easily measurable scoring system for prediction of severe or febrile neutropenia in the first chemotherapy cycle of patients with solid tumors or lymphoma. METHODS: This prospective cohort study included consecutive patients at a tertiary referral hospital. Many clinical and laboratory-independent variables were measured at baseline...
May 7, 2018: Supportive Care in Cancer: Official Journal of the Multinational Association of Supportive Care in Cancer
https://www.readbyqxmd.com/read/29723393/phase-2-trial-of-bortezomib-in-combination-with-rituximab-plus-hyperfractionated-cyclophosphamide-vincristine-doxorubicin-and-dexamethasone-alternating-with-bortezomib-rituximab-methotrexate-and-cytarabine-for-untreated-mantle-cell-lymphoma
#2
Jorge E Romaguera, Michael Wang, Lei Feng, Luis E Fayad, Frederick Hagemeister, Peter McLaughlin, M Alma Rodriguez, Michelle Fanale, Robert Orlowski, Larry W Kwak, Sattva Neelapu, Yasuhiro Oki, Barbara Pro, Anas Younes, Felipe Samaniego, Nathan Fowler, Kimberly Hartig, Marisa Valentinetti, Judy Smith, Peggy Ford, Adam Naig, L Jeffrey Medeiros, Hagop M Kantarjian, Andre Goy
BACKGROUND: Although the outcomes of patients with mantle cell lymphoma (MCL) have improved, there is still no cure. Bortezomib has a 33% response rate in relapsed/refractory MCL and has shown additive and/or synergistic effects in preclinical trials with known effective agents. METHODS: This is a report of a prospective phase 2 trial of bortezomib added to rituximab plus hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (BzR-hyperCVAD)/rituximab, high-dose methotrexate, and high-dose cytarabine (BzR-MA) for 95 patients with newly diagnosed MCL...
May 3, 2018: Cancer
https://www.readbyqxmd.com/read/29722200/emergency-department-presentations-in-early-stage-breast-cancer-patients-receiving-adjuvant-and-neoadjuvant-chemotherapy
#3
Monica Tang, Patrick Horsley, Craig R Lewis
(Neo)adjuvant chemotherapy for early stage breast cancer is associated with side-effects, resulting in increased emergency department (ED) presentations. Treatment-related toxicity can affect quality of life, compromise chemotherapy delivery and treatment outcomes, and increase healthcare use. We performed a retrospective study of ED presentations in patients receiving curative chemotherapy for early breast cancer to identify factors contributing to ED presentations. Of 102 patients, 39 (38%) presented to ED within 30 days of chemotherapy, resulting in 63 ED presentations in total...
May 2018: Internal Medicine Journal
https://www.readbyqxmd.com/read/29627080/assessment-and-management-of-diarrhea-following-vegf-receptor-tki-treatment-in-patients-with-ovarian-cancer
#4
REVIEW
Joyce Liu, Shibani Nicum, Peter Reichardt, Kenneth Croitoru, Beate Illek, Manuela Schmidinger, Catherine Rogers, Christin Whalen, Gordon C Jayson
Angiogenesis is a proven clinical target for the treatment of advanced epithelial ovarian cancer. Vascular endothelial growth factor receptor tyrosine kinase inhibitors (VEGFR-TKIs) offer patients potential new treatment regimens as they can be given as monotherapy, in combination with poly(ADP-ribose) polymerase (PARP) inhibitors, or with and following cytotoxic chemotherapy. If VEGFR-TKIs are licensed for use in ovarian cancer, patients will require prompt and effective management of adverse events, including diarrhea, to optimize compliance and benefit...
April 4, 2018: Gynecologic Oncology
https://www.readbyqxmd.com/read/29608680/extended-versus-bolus-infusion-of-broad-spectrum-%C3%AE-lactams-for-febrile-neutropenia-an-unblinded-randomized-trial
#5
Ron Ram, Yael Halavy, Odelia Amit, Yael Paran, Eugene Katchman, Bruria Yachini, Svetlana Kor, Irit Avivi, Ronen Ben-Ami
Background: Febrile neutropenia may be a sign of severe infection, and is associated with significant morbidity and mortality in high-risk patients with hematologic malignancies. Extended infusion of β-lactam antibiotics is associated with greater clinical response than is bolus infusion in non-neutropenic critically ill patients, but data are lacking for febrile neutropenic patients. Methods: We designed a single-center, non-blinded randomized trial comparing extended infusion (4 hours) and bolus infusion (30 minutes) of piperacillin-tazobactam or ceftazidime in high-risk patients with febrile neutropenia...
March 28, 2018: Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America
https://www.readbyqxmd.com/read/29605592/aflibercept-plus-folfiri-in-the-real-life-setting-safety-and-quality-of-life-data-from-the-italian-patient-cohort-of-the-aflibercept-safety-and-quality-of-life-program-study
#6
Alessandro Pastorino, Maria Di Bartolomeo, Evaristo Maiello, Vincenzo Iaffaioli, Libero Ciuffreda, Gianpiero Fasola, Francesco Di Costanzo, Giovanni Luca Frassineti, Paolo Marchetti, Carlotta Antoniotti, Francesco Leone, Alberto Zaniboni, Giuseppe Aprile, Chiara Zilocchi, Alberto Sobrero, Roberto Bordonaro
BACKGROUND: Aflibercept combined with FOLFIRI (folinic acid, 5-fluorouracil, irinotecan) as second-line treatment of metastatic colorectal cancer (mCRC) significantly improved survival compared with FOLFIRI alone in the pivotal VELOUR (aflibercept vs. placebo in combination with irinotecan and 5-fluorouracil in the treatment of patients with metastatic colorectal cancer after failure of an oxaliplatin-based regimen) trial. No quality-of-life assessment was performed in VELOUR; therefore, the ASQoP (Aflibercept Safety and Quality-of-Life Program) trial was designed to capture the safety and health-related quality of life (HRQL)...
March 8, 2018: Clinical Colorectal Cancer
https://www.readbyqxmd.com/read/29550383/liposomal-grb2-antisense-oligodeoxynucleotide-bp1001-in-patients-with-refractory-or-relapsed-haematological-malignancies-a-single-centre-open-label-dose-escalation-phase-1-1b-trial
#7
Maro Ohanian, Ana Tari Ashizawa, Guillermo Garcia-Manero, Naveen Pemmaraju, Tapan Kadia, Elias Jabbour, Farhad Ravandi, Gautam Borthakur, Michael Andreeff, Marina Konopleva, Miranda Lim, Sherry Pierce, Susan O'Brien, Yesid Alvarado, Srdan Verstovsek, William Wierda, Hagop Kantarjian, Jorge Cortes
BACKGROUND: Activating mutations of tyrosine kinases are common in leukaemias. Oncogenic tyrosine kinases use the growth factor receptor-bound protein 2 (Grb2) for signal transduction, leading to activation of mitogen-activated protein kinase (MAPK) 1 and MAPK3 (ERK2 and ERK1). We hypothesised that inhibition of Grb2 would suppress ERK1 and ERK2 activation and inhibit leukaemia progression. To inhibit Grb2, a liposome-incorporated antisense oligodeoxynucleotide that blocks Grb2 protein expression, BP1001, was developed...
April 2018: Lancet Haematology
https://www.readbyqxmd.com/read/29466965/neutropenia-after-intravenous-immunoglobulin-therapy-is-associated-with-coronary-artery-lesions-in-children-with-kawasaki-disease-a-case-control-study
#8
Zhenquan Wang, Fengfeng Weng, Chen Li, Hongying Shi, Zhangke Tang, Huixian Qiu, Yue'e He, Rongzhou Wu, Maoping Chu
BACKGROUND: To evaluate differences in laboratory parameters, clinical presentation, and incidence of coronary artery lesions (CAL) between children with neutropenic and non-neutropenic Kawasaki disease (KD). METHODS: All consecutive KD patients that presented to the Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University in Wenzhou, China between January 2005 and December 2015 were included in this study. Patients were divided into two groups (KD with neutropenia (NKD) and KD without neutropenia (NNKD)) based on whether or not they developed neutropenia during the course of treatment...
February 21, 2018: BMC Pediatrics
https://www.readbyqxmd.com/read/29448851/salvage-tigecycline-in-high-risk-febrile-neutropenic-patients-with-hematological-malignancies-a-prospective-multicenter-study
#9
Xin-Ping Zhou, Xiu-Jin Ye, Jian-Ping Shen, Jian-Ping Lan, Hui-Fang Jiang, Jin Zhang, Xue-Jin Zhang, Li Li, Shen-Xian Qian, Hong-Yan Tong
The purpose of this prospective, multi-center study was to examine the efficacy and safety of tigecycline as empirical treatment in neutropenic patients with hematological malignancies who failed to respond to first-line antibiotics. A total of 125 patients with persistent fever (>72 h) despite first-line antibiotics received empirical treatment with tigecycline (loading dose of 100 mg, followed by 50 mg every 12 h). The use of other antimicrobial agents was not restricted. Treatment success rate was 68...
February 16, 2018: Leukemia & Lymphoma
https://www.readbyqxmd.com/read/29378706/-in-vivo-pharmacokinetics-and-pharmacodynamics-of-apx001-against-candida-spp-in-a-neutropenic-disseminated-candidiasis-mouse-model
#10
Miao Zhao, Alexander J Lepak, Brian VanScoy, Justin C Bader, Karen Marchillo, Jamie Vanhecker, Paul G Ambrose, David R Andes
APX001 is the prodrug of APX001A, which is a first-in-class small molecule with a unique mechanism of action that inhibits the fungal enzyme Gwt1 in the glycosylphosphatidylinositol (GPI) biosynthesis pathway. The goal of the present study was to determine which pharmacokinetic/pharmacodynamic (PK/PD) index and magnitude best correlated with efficacy in the murine disseminated candidiasis model for Candida albicans ( n = 5), C. glabrata ( n = 5), and C. auris ( n = 4). MIC values ranged from 0.002 to 0.03 mg/liter for C...
April 2018: Antimicrobial Agents and Chemotherapy
https://www.readbyqxmd.com/read/29218692/euro-b-o-s-s-a-european-study-on-chemotherapy-in-bone-sarcoma-patients-aged-over-40-outcome-in-primary-high-grade-osteosarcoma
#11
Stefano Ferrari, Stefan S Bielack, Sigbjørn Smeland, Alessandra Longhi, Gerlinde Egerer, Kirsten Sundby Hall, Davide Donati, Matthias Kevric, Otte Brosjö, Alessandro Comandone, Mathias Werner, Odd Monge, Emanuela Palmerini, Wolfgang E Berdel, Bodil Bjerkehagen, Anna Paioli, Sylvie Lorenzen, Mikael Eriksson, Marco Gambarotti, Per-Ulf Tunn, Nina L Jebsen, Marilena Cesari, Thekla von Kalle, Virginia Ferraresi, Rudolf Schwarz, Rossella Bertulli, Anne-Katrin Kasparek, Giovanni Grignani, Fatime Krasniqi, Benjamin Sorg, Stefanie Hecker-Nolting, Piero Picci, Peter Reichardt
INTRODUCTION: The EUROpean Bone Over 40 Sarcoma Study (EURO-B.O.S.S.) was the first prospective international study for patients 41-65 years old with high-grade bone sarcoma treated with an intensive chemotherapy regimen derived from protocols for younger patients with high-grade skeletal osteosarcoma. METHODS: Chemotherapy based on doxorubicin, cisplatin, ifosfamide, and methotrexate was suggested, but patients treated with other regimens at the investigators' choice were also eligible for the study...
December 5, 2017: Tumori
https://www.readbyqxmd.com/read/29203480/pharmacodynamics-of-a-long-acting-echinocandin-cd101-in-a-neutropenic-invasive-candidiasis-murine-model-using-an-extended-interval-dosing-design
#12
Alexander J Lepak, Miao Zhao, Brian VanScoy, Paul G Ambrose, David R Andes
Echinocandins are important in the prevention and treatment of invasive candidiasis but limited by current dosing regimens that include daily intravenous administration. The novel echinocandin CD101 has a prolonged half-life of approximately 130 h in humans, making it possible to design once-weekly dosing strategies. The present study examined the pharmacodynamic activity of CD101 using the neutropenic invasive candidiasis mouse model against select Candida albicans ( n = 4), C. glabrata ( n = 3), and C. parapsilosis ( n = 3) strains...
February 2018: Antimicrobial Agents and Chemotherapy
https://www.readbyqxmd.com/read/29178248/no-indication-of-increased-infection-rates-using-low-dose-alemtuzumab-instead-of-anti-thymocyte-globulin-as-graft-versus-host-disease-prophylaxis-before-allogeneic-stem-cell-transplantation
#13
Thomas Neumann, Laila Schneidewind, Thomas Thiele, Daniel Pink, Meike Schulze, Christian Schmidt, William Krüger
BACKGROUND: Alemtuzumab as part of the conditioning protocol is effective in reducing graft-versus-host disease (GvHD), but may be associated with increased infection rates, especially when using high doses (ie, 100 mg). METHODS: We performed a retrospective, single-center, case-control study analyzing the rates of neutropenic fever, cytomegalovirus (CMV) reactivation, Epstein-Barr virus (EBV) reactivation, clinical manifest toxoplasmosis, and clinical manifest human herpesvirus-6 (HHV6) infection using low-dose alemtuzumab in comparison with anti-thymocyte globulin (ATG) as GvHD prophylaxis before allogeneic stem cell transplantation...
February 2018: Transplant Infectious Disease: An Official Journal of the Transplantation Society
https://www.readbyqxmd.com/read/29157145/clostridium-difficile-treatment-in-neutropenic-patients-clinical-outcomes-of-metronidazole-vancomycin-combinations-and-switch-therapy
#14
Jennifer D Tieu, Sarah A Schmidt, Jamie L Miller, Katherine E Kupiec, Grant H Skrepnek, Connie Liu, Winter J Smith
Background Clostridium difficile infection treatment guidelines exist for immunocompetent patients; however, there is a paucity of data evaluating clinical outcomes and time to C. difficile-associated diarrhea resolution in neutropenic patients. Objective To assess clinical outcomes in neutropenic patients treated with metronidazole, oral vancomycin, the combination of metronidazole plus oral vancomycin, and switch of metronidazole to oral vancomycin. Methods This retrospective, observational cohort study assessed adult neutropenic inpatients with C...
January 1, 2017: Journal of Oncology Pharmacy Practice
https://www.readbyqxmd.com/read/29149294/pharmacokinetics-pharmacodynamics-of-systemically-administered-polymyxin-b-against-klebsiella-pneumoniae-in-mouse-thigh-and-lung-infection-models
#15
Cornelia B Landersdorfer, Jiping Wang, Veronika Wirth, Ke Chen, Keith S Kaye, Brian T Tsuji, Jian Li, Roger L Nation
Background: The pharmacokinetic/pharmacodynamic (PK/PD) relationship for polymyxin B against Klebsiella pneumoniae infections is not known. Methods: Dose-fractionation studies with subcutaneous polymyxin B were conducted in neutropenic mice in which infection with three strains of K. pneumoniae had been produced in thighs or lungs. Dosing (thigh infection 0.5-120 mg/kg/day; lung infection 5-120 mg/kg/day) commenced 2 h after inoculation, and bacterial burden was measured 24 h later...
February 1, 2018: Journal of Antimicrobial Chemotherapy
https://www.readbyqxmd.com/read/29130946/considerations-about-the-use-of-a-loading-dose-of-daptomycin-in-a-neutropenic-murine-thigh-infection-model-with-methicillin-resistant-staphylococcus-aureus-infection
#16
Hideo Kato, Mao Hagihara, Eriko Murakami, Hiroyuki Suematsu, Naoya Nishiyama, Yusuke Koizumi, Yuka Yamagishi, Bunji Uno, Hiroshige Mikamo
Previous clinical studies have showed the clinical benefits of the initiation of treatment with a daptomycin (DAP) loading dose, but only a few studies have evaluated its antimicrobial benefits. We evaluated the efficacy of a DAP loading dose against methicillin-resistant Staphylococcus aureus (MRSA) infections in a neutropenic murine thigh infection model. Three MRSA isolates (DAP MIC: 0.5, 1, and 2 mg/L) were tested. Four DAP regimens simulating human concentration-time profiles, i.e., (i) day 1: 8 mg/kg and day 2: 6 mg/kg, (ii) days 1 and 2: 6 mg/kg/day, (iii) day 1: 8 mg/kg and day 2: 4 mg/kg, and (iv) days 1 and 2: 4 mg/kg/day, were administered to the mice...
2018: Chemotherapy
https://www.readbyqxmd.com/read/29109160/activity-of-meropenem-vaborbactam-in-mouse-models-of-infection-due-to-kpc-producing-carbapenem-resistant-enterobacteriaceae
#17
Mojgan Sabet, Ziad Tarazi, Thomas Nolan, Jonathan Parkinson, Debora Rubio-Aparicio, Olga Lomovskaya, Michael N Dudley, David C Griffith
Meropenem-vaborbactam (Vabomere) is highly active against Gram-negative pathogens, especially Klebsiella pneumoniae carbapenemase (KPC)-producing, carbapenem-resistant Enterobacteriaceae The objective of these studies was to evaluate the efficacy of meropenem alone and in combination with vaborbactam in mouse thigh and lung infection models. Thighs or lungs of neutropenic mice were infected with KPC-producing carbapenem-resistant Enterobacteriaceae , with meropenem MICs ranging from ≤0.06 to 8 mg/liter in the presence of 8 mg/liter vaborbactam...
January 2018: Antimicrobial Agents and Chemotherapy
https://www.readbyqxmd.com/read/29100977/evaluation-of-weekly-paclitaxel-plus-carboplatin-followed-by-anthracycline-chemotherapy-on-the-neoadjuvant-treatment-of-patients-with-triple-negative-breast-cancer
#18
Aurelio B Castrellon, Michel Velez, Steven M Nguyen, Marcelo Blaya, Sandra Barnick, Katerine Dumais, Nicholas LeCroy, Luis E Raez
OBJECTIVE: To evaluate the effectiveness and tolerability of neoadjuvant chemotherapy with weekly paclitaxel in combination with weekly carboplatin area under curve 2 followed by anthracycline chemotherapy. PATIENTS AND METHODS: This is a retrospective review of electronic medical records of patients (N = 32) with stage 1c-III triple-negative breast cancer. Patients received neoadjuvant chemotherapy with paclitaxel 80 mg/m2 once per week for 12 weeks in combination with carboplatin area under curve 2 once per week for 12 weeks (wP + wCb), followed by a standard anthracycline regimen including either doxorubicin 60 mg/m2 and cyclophosphamide 600 mg/m2 every 2 or 3 weeks, or epirubicin 90 mg/m2 and cyclophosphamide 600 mg/m2 every 3 weeks for four cycles with myeloid growth factor support...
March 2018: Hematology/oncology and Stem Cell Therapy
https://www.readbyqxmd.com/read/29072402/outcomes-of-high-risk-patients-with-febrile-neutropenia-at-a-tertiary-care-center
#19
Asif Husain Osmani, Adnan Abdul Jabbar, Manesh Kumar Gangwani, Bilal Hassan
Fever during chemotherapy-induced neutropenia continues to be a major cause of morbidity and mortality in cancer patients. Mortality depends on the duration and degree of neutropenia, bacteremia, sepsis, performance status, comorbidities and other parameters. The highest mortality rates in cancer patients hospitalized with febrile neutropenia (FN) are observed in those with documented infection. The objectives of the study were to present available tools for risk assessment, to review pathogens causing infections in adult FN patients and to assess outcomes...
October 26, 2017: Asian Pacific Journal of Cancer Prevention: APJCP
https://www.readbyqxmd.com/read/29050538/evaluation-of-the-head-and-neck-cancer-patient-population-and-the-incidence-of-hospitalization-at-an-academic-medical-center
#20
Lindsay A Hazelden, Matthew J Newman, Stephanie Shuey, Julie M Waldfogel, Victoria T Brown
Purpose Patients with head and neck cancer are at risk for disease- and treatment-related toxicities that may be severe enough to require hospitalization. The risk factors associated with hospitalization in these patients are not well defined. Methods We conducted a single-center, retrospective observational study of patients with head and neck cancer receiving chemotherapy at an academic medical center infusion clinic in a one-year period. The primary objective was to characterize the head and neck cancer population at an academic medical center...
January 1, 2017: Journal of Oncology Pharmacy Practice
keyword
keyword
65238
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"